Association study of a functional variant on ABCG2 gene with sunitinib-induced severe adverse drug reaction

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Low, Siew Kee ^a,b   Fukunaga, Koya ^a   Takahashi, Atsushi ^a   Matsuda, Koichi ^c   Hongo, Fumiya ^d   Nakanishi, Hiroyuki ^d   Kitamura, Hiroshi ^e   Inoue, Takamitsu ^f   Kato, Yoichiro ^g   Tomita, Yoshihiko ^h   Fukasawa, Satoshi ⁱ   Tanaka, Tomoaki ^j   Nishimura, Kazuo ^k   Uemura, Hirotsugu ^l   Hara, Isao ^m   Fujisawa, Masato ⁿ   Matsuyama, Hideyasu ^o   Hashine, Katsuyoshi ^p   Tatsugami, Katsunori ^q   Enokida, Hideki ^r   Kubo, Michiaki ^a   Miki, Tsuneharu ^d   Mushiroda, Taisei ^a   more..

^a Institute of Physical and Chemical Research   (Japan)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

^h YAMAGATA UNIVERSITY   (Japan)

ⁱ CHIBA CANCER CENTER   (Japan)

^j OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^l KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁿ KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^q KYUSHU UNIVERSITY   (Japan)

^r KAGOSHIMA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; SUNITINIB; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR PROTEIN;

ABCG2 GENE; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEUTROPENIA; POLYMERASE CHAIN REACTION; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, RENAL CELL; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETIC ASSOCIATION STUDY; GENETICS; JAPAN; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INDOLES; JAPAN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLES; THROMBOCYTOPENIA;

EID: 84978985863     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148177     Document Type: Article

References (29)

1. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. The Journal of pharmacology and experimental therapeutics. 2005; 315(3):971-9. Epub 2005/07/09. doi: 10.1124/jpet.105.084145 PMID: 16002463.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2004; 350(21):2129-39. Epub 2004/05/01. doi: 10.1056/NEJMoa040938 PMID: 15118073.
3. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(36):13306-11. Epub 2004/08/27. doi: 10.1073/pnas.0405220101 PMID: 15329413; PubMed Central PMCID: PMC516528.
4. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305(5687):1163-7. Epub 2004/07/31. doi: 10.1126/science.1101637 PMID: 15284455.
5. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(1):327-37. Epub 2003/01/23. PMID: 12538485.
6. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(7):884-96. Epub 2007/03/01. doi: 10.1200/JCO.2006.06.3602 PMID: 17327610.
7. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(1):25-35. Epub 2005/11/30. doi: 10.1200/JCO.2005.02.2194 PMID: 16314617.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine. 2007; 356(2):115-24. Epub 2007/01/12. doi: 10.1056/NEJMoa065044 PMID: 17215529.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(22):3584-90. Epub 2009/06/03. doi: 10.1200/JCO.2008.20.1293 PMID: 19487381; PubMed Central PMCID: PMC3646307.
10. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical therapeutics. 2007; 29(7):1338-53. Epub 2007/09/11. doi: 10.1016/j.clinthera.2007.07.022 PMID: 17825686.
11. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA: the journal of the American Medical Association. 2006; 295(21):2516-24. Epub 2006/06/08. doi: 10.1001/jama.295.21.2516 PMID: 16757724.
12. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Japanese journal of clinical oncology. 2010; 40(3):194-202. Epub 2009/11/10. doi: 10.1093/jjco/hyp146 PMID: 19897852.
13. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, et al. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer research and treatment: official journal of Korean Cancer Association. 2009; 41(2):67-72. Epub 2009/08/27. doi: 10.4143/crt.2009.41.2.67 PMID: 19707503; PubMed Central PMCID: PMC2731208.
14. Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma. International journal of clinical oncology. 2013; 18(1):81-6. Epub 2011/11/19. doi: 10.1007/s10147-011-0347-7 PMID: 22095244.
15. Yoo C, Kim JE, Lee JL, Ahn JH, Lee DH, Lee JS, et al. The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Japanese journal of clinical oncology. 2010; 40(10):980-5. Epub 2010/05/12. doi: 10.1093/jjco/hyq073 PMID: 20457723.
16. Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012; 118(7):1946-54. Epub 2011/09/02. doi: 10.1002/cncr.26491 PMID: 21882181; PubMed Central PMCID: PMC4124607.
17. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British journal of cancer. 2013; 108(4):887-900. Epub 2013/03/07. doi: 10.1038/bjc.2012.548 PMID: 23462807; PubMed Central PMCID: PMC3590652.
18. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta oncologica. 2014; 53(1):103-12. Epub 2013/02/21. doi: 10.3109/0284186X.2013.770600 PMID: 23421954.
19. Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British journal of cancer. 2013; 108(5):1126-32. Epub 2013/03/21. doi: 10.1038/bjc.2012.501 PMID: 23511629; PubMed Central PMCID: PMC3619056.
20. Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, et al. CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European urology. 2015; 68(4):621-9. Epub 2015/05/02. doi: 10.1016/j.eururo.2015.04.018 PMID: 25930089.
21. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clinical pharmacology and therapeutics. 2012; 92(4):503-10. Epub 2012/09/06. doi: 10.1038/clpt.2012.136 PMID: 22948895.
22. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, et al. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer chemotherapy and pharmacology. 2013; 72(4):825-35. Epub 2013/09/10. doi: 10.1007/s00280-013-2258-y PMID: 24013576.
23. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Advanced drug delivery reviews. 2009; 61(1):26-33. Epub 2008/12/30. doi: 10.1016/j.addr.2008.07.003 PMID: 19111841.
24. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et biophysica acta. 2002; 1587(2-3):318-25. Epub 2002/06/27. PMID: 12084474.
25. Vlaming ML, Lagas JS, Schinkel AH. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Advanced drug delivery reviews. 2009; 61(1):14-25. Epub 2009/01/03. doi: 10.1016/j.addr.2008.08.007 PMID: 19118589.
26. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Molecular cancer therapeutics. 2002; 1(8):611-6. Epub 2002/12/14. PMID: 12479221.
27. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. International journal of cancer Journal international du cancer. 2004; 109(2):238-46. Epub 2004/01/30. doi: 10.1002/ijc.11669 PMID: 14750175.
28. Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, et al. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug metabolism and pharmacokinetics. 2012; 27(6):631-9. Epub 2012/06/08. PMID: 22673043.
29. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008; 9(8):1005-9. Epub 2008/08/07. doi: 10.2217/14622416.9.8.1005 PMID: 18681776.